Table 3. Clinical characteristics of... | American Society of Hematology

Table 3.

Clinical characteristics of patients with AML whose samples were used for in vivo experiments

Patient No.	OxPhosi sensitivity	Diagnosis	Mutation status
27	Sensitive	AML	FLT3-ITD, CEPBA, IDH1, NPM1, NRAS
28	Sensitive	AML	FLT3-ITD, DNMT3A, IDH1, KIT, NPM1
29	Sensitive	AMML	FLT3-ITD, IDH1, NPM1
30	Resistant	AML	FLT3-ITD, DNMT3A, NPM1, TP53
31	Resistant	AML	FLT3-ITD, DNMT3A, IDH2, NPM1
32	Resistant	AML	FLT3-ITD, DNMT3A, IDH1, NPM1
33	Resistant	AML	FLT3-ITD, DNMT3A, EGFR, IDH1, NPM1, TET2

Patient No.	OxPhosi sensitivity	Diagnosis	Mutation status
27	Sensitive	AML	FLT3-ITD, CEPBA, IDH1, NPM1, NRAS
28	Sensitive	AML	FLT3-ITD, DNMT3A, IDH1, KIT, NPM1
29	Sensitive	AMML	FLT3-ITD, IDH1, NPM1
30	Resistant	AML	FLT3-ITD, DNMT3A, NPM1, TP53
31	Resistant	AML	FLT3-ITD, DNMT3A, IDH2, NPM1
32	Resistant	AML	FLT3-ITD, DNMT3A, IDH1, NPM1
33	Resistant	AML	FLT3-ITD, DNMT3A, EGFR, IDH1, NPM1, TET2